Lincoln Pharma Q1 FY27 net profit up 30.9% YoY to Rs 36.23 cr

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹591.50

prior close

₹628.25

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+4.9% vs market

Pharmaceuticals peers, median of 166sector+0.1%+4.9% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 4.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

+0.1

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.2+4.9+0.1+4.9

Next day

+3.5+0.2+3.3-0.3+3.8

+5.5+0.4+5.1-0.2+5.7

+4.4+0.7+3.7-0.4+4.8

+4.5+0.1+4.3-1.5+5.9

+5.1+0.7+4.4-0.9+6.0

+3.4+1.2+2.3-0.6+4.1

15d

+5.6+0.7+4.8+0.3+5.3

+1.4-1.2+2.6-0.2+1.6

-6.9-1.1-5.8-2.3-4.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharma reported consolidated Q1 FY27 net profit of Rs 36.23 crore, up 30.9% YoY from Rs 27.68 crore. Total income rose 19% to Rs 201.55 crore. EBITDA grew 32.3% to Rs 51.70 crore. EPS stood at Rs 18.09. Company targets Rs 1,000 crore revenue in 3 years, remains net-debt free, FII holding at 4.60%.

Likely market impact

Strong quarterly results with over 30% YoY profit growth and expanding EBITDA margins signal healthy business momentum for shareholders.